<DOC>
	<DOCNO>NCT00416429</DOCNO>
	<brief_summary>RATIONALE : Medroxyprogesterone may help shrink slow growth kidney cancer . Interferon may interfere growth tumor cell . Aldesleukin may stimulate white blood cell kill tumor cell . It yet know whether give medroxyprogesterone , interferon , aldesleukin alone effective give interferon together aldesleukin treat kidney cancer . PURPOSE : This randomized phase III trial study medroxyprogesterone , interferon , aldesleukin see well work give alone compare interferon combine aldesleukin treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Medroxyprogesterone Interferon and/or Aldesleukin Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall survival patient metastatic renal cell adenocarcinoma treat medroxyprogesterone v recombinant interferon alfa-2a and/or aldesleukin . Secondary - Determine objective response rate ( complete partial ) patient treat regimen . - Determine progression-free survival patient treat regimen . - Determine toxicity regimens patient . - Evaluate quality life patient induction treatment regimen ( week 10 ) . OUTLINE : This randomize , control , open-label , multicenter study . Patients randomize 1 4 treatment arm . - Arm I ( medroxyprogesterone ) : Patients receive oral medroxyprogesterone daily 12 week . Patients may receive second 12-week course presence respond stable disease . Quality life assess baseline week 12 24 . - Arm II ( recombinant interferon alfa-2a ) : Patients receive recombinant interferon alfa-2a subcutaneously ( SC ) 3 time weekly 12 week . Patients may receive second 12-week course presence respond stable disease . Quality life assess arm I . - Arm III ( aldesleukin ) : Patients receive aldesleukin SC twice daily day 1-5 , 8 , 9 , 15 , 16 , 22 , 23 daily day 10-12 , 17-19 , 24-26 . Courses repeat begin week 6 , 13 , 20 . Quality life assess baseline week 10 24 . - Arm IV ( recombinant interferon alfa-2a aldesleukin ) : Patients receive recombinant interferon alfa-2a arm II receive aldesleukin arm III . Quality life assess arm III . After completion study treatment , patient follow periodically 5 year annually thereafter . PROJECTED ACCRUAL : A total 456 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell adenocarcinoma , meet 1 follow criterion : More 1 metastatic site good performance status ( Karnofsky score 80100 % ) Sole metastatic site Karnofsky score = 80 % Karnofsky 90 % 100 % eligible No combination several metastatic site liver metastasis time interval primary tumor metastasis &lt; 1 year Nonmeasurable disease and/or number lesion must confirm histologically progressive disease The following metastasis allow : Lung without mediastinum lymph node Bone Pleura ( solid liquid positive cytology ) Thoracic lymph node Abdominal lymph node Superficial lymph node Liver Subcutaneous skin/tissue Contralateral kidney Nephrectomy site Other organ Prior metastasis allow provide follow criterion meet : Evidence progressive disease within past 3 month Metastases evaluate noninvasive method No evidence active brain metastasis Prior brain metastasis allow provide follow criterion meet : Disease stable Reductive therapy ( surgery radiotherapy ) complete least 3 week prior study entry Metastases progress ( confirm CT scan MRI ) No concurrent corticosteroid require PATIENT CHARACTERISTICS : See Disease Characteristics Creatinine &lt; 1.8 mg/dL Hematocrit ≥ 30 % WBC ≥ 4,000/mm^3 Platelet count ≥ 120,000/mm^3 Bilirubin normal LVEF ≥ 50 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity No severe infection require antibiotic therapy No chronic hepatitis No severe lung , liver kidney condition would preclude study treatment No hepatitis B surface antigen positivity No severe neuropsychiatric condition epilepsy No serious thromboembolitic disorder No severe cardiac dysfunction ( e.g. , congestive heart failure , uncontrolled hypertension , serious arrhythmia , coronary disease ) No prior concurrent primary malignancy except basal cell skin cancer carcinoma situ cervix No geographical , psychological , familial condition would preclude study participation PRIOR CONCURRENT THERAPY : More 6 week since prior widefield radiotherapy No prior systemic chemotherapy No prior organ transplantation No prior cytokines No concurrent hormonal therapy No concurrent anticancer chemotherapy No concurrent corticosteroids No concurrent immunotherapy No concurrent investigational agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>